Forecast Ledgerinterventional psychiatry and psychedelic medicineQuoted, dated predictions scored against public outcomes under one written method. Every score links to the words, the rule and the evidence.

Not admitted · Not a forecast

Rules 1.1.0 · as of 14 Sep 2026

Quote

Not a forecast

“Personally, I suspect that in the right patients, Spravato and ketamine are both effective, and an underpowered study isn’t changing my perspective too much.”
· Does One Negative Study Ruin Ketamine For Psychiatry? · substack post

The author rejects the implication of the negative KARMA-Dep 2 trial (ketamine vs. midazolam) and expects ketamine and Spravato efficacy to hold up in appropriately selected patients as further evidence accrues.

Descriptive, retrospective, or a statement of preference; no future state asserted.